I came across a recent article discussing Degrader-Antibody Conjugates (DACs) and their potential to transform drug discovery, especially for previously undruggable targets
Potential for Discovery: Opens up opportunities to explore new treatments for joint health, cardiovascular diseases, and chronic pain
A large prospective cohort study that tracked over 1,700 patients demonstrated that patients who underwent a Roux-en-Y gastric bypass lost an excess 21% of their body mass normalized to their non-surgical matched controls at the 10 year point (corresponding to 35 kg (~77 lbs) greater weight loss)
I thought Id be an actress or ballerina, but I had to take a science class and that one sounded cool, and I absolutely was a fish in water
Its unique triple-agonist design, strong clinical results, and growing popularity have made it a leading topic among peptide enthusiasts across the United States
Rapid weight loss with GLP1 receptor agonists can come at the cost of skeletal muscle, potentially undermining metabolic and functional outcomes
